Eventide Healthcare Life Fund Investor Sentiment

ETCHX Fund  USD 31.66  0.80  2.59%   
Slightly above 55% of Eventide Healthcare's investors are presently thinking to get in. The analysis of overall sentiment of trading Eventide Healthcare Life mutual fund suggests that some investors are interested at this time. Eventide Healthcare's investing sentiment can be driven by a variety of factors including economic data, Eventide Healthcare's earnings reports, geopolitical events, and overall market trends.
  
over a year ago at news.google.com         
EVENTIDE HEALTHCARE LIFE SCIENCES FUND CELEBRATES ... - Valdosta Daily Times
Google News at Macroaxis
over a year ago at news.google.com         
Rain Oncology Multiple Data Catalysts In 2023 For This Precision ... - Seeking Alpha
Google News at Macroaxis
2 days ago at news.google.com         
Collegium Pharmaceutical, Inc. Receives Average Recommendation of Moderate Buy from Brokerages - Mar...
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Empowered Funds LLC Acquires New Position in Collegium Pharmaceutical, Inc.
news
over a week ago at gurufocus.com         
Rubric Capital Management LP Adjusts Stake in Collegium Pharmaceutical Inc
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Is Collegium Pharmaceutical a Great Value Stock Right Now?
Yahoo News
over a week ago at gurufocus.com         
Collegium Pharmaceutical Inc Stock Price Down 3.67 percent on Nov 12
Gurufocus Stories at Macroaxis
over two weeks ago at zacks.com         
Is the Options Market Predicting a Spike in Collegium Pharmaceutical Stock?
zacks News
over two weeks ago at finance.yahoo.com         
Collegium Pharmaceutical Inc Q3 2024 Earnings Call Highlights Record Revenue Growth and ...
Yahoo News
over two weeks ago at finance.yahoo.com         
Collegium Pharmaceutical Q3 Earnings Snapshot
Yahoo News
over two weeks ago at finance.yahoo.com         
Heres What Key Metrics Tell Us About Collegium Pharmaceutical Q3 Earnings
Yahoo News
over two weeks ago at gurufocus.com         
What To Expect From Collegium Pharmaceutical Inc Q3 2024 Earnings
Gurufocus Stories at Macroaxis
over a year ago at finance.yahoo.com         
Antibody Drug Conjugates Global Market Report 2023
Yahoo News
over three months ago at seekingalpha.com         
Tectonic, AVROBIO complete merger, announce 130.7M private placement
seekingalpha News
over three months ago at news.google.com         
Gabelli Funds LLC Invests 467000 in AVROBIO, Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
AVROBIO, Inc. Short Interest Up 11.3 percent in May - MarketBeat
Google News at Macroaxis
over six months ago at investing.com         
Avrobio executive buys shares worth over 970k
Investing News at Macroaxis
over six months ago at investorplace.com         
AVRO Stock Earnings Avrobio Beats EPS for Q1 2024
sbwire news
over six months ago at news.google.com         
AVROBIO Options Chain Prices 2024 - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
AVROBIO Posts Quarterly Earnings Results - MarketBeat
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
AVROBIO, Inc. Sees Significant Drop in Short Interest
news
over six months ago at benzinga.com         
SHAREHOLDER UPDATE Halper Sadeh LLC Investigates AXNX, KAMN, JNPR, AVRO
benzinga news
over six months ago at news.google.com         
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates...
Google News at Macroaxis
3 days ago at news.google.com         
SUPN Operating Margin percent 22.67 percent - GuruFocus.com
Google News at Macroaxis
few days ago at news.google.com         
Mutual of America Capital Management LLC Sells 75,782 Shares of Supernus Pharmaceuticals, Inc. - Mar...
Google News at Macroaxis
over a week ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Acquires New Holdings in BioSig Technologies Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Acquires Shares in Purple Biotech Ltd
Gurufocus Stories at Macroaxis
over a week ago at investors.com         
Supernus Pharmaceuticals Meets 80-Plus Relative Strength Rating Benchmark
Investors Business Daily at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 20000 shares by Newhall Charles W Iii of Supernus Pharmaceuticals at 9.13 subject to ...
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Disposition of 125000 shares by Jack Khattar of Supernus Pharmaceuticals at 9.13 subject to Rule 16b...
news
over two weeks ago at insidermonkey.com         
Supernus Pharmaceuticals, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over two weeks ago at thelincolnianonline.com         
Supernus Pharmaceuticals Issues Earnings Results, Beats Estimates By 0.25 EPS
news
over two weeks ago at investing.com         
Earnings call Supernus Pharmaceuticals reported a significant increase in total revenue
Investing News at Macroaxis
few days ago at gurufocus.com         
Insider Sell Alert Karin Eastham Sells 14,731 Shares of Veracyte Inc
Gurufocus Stories at Macroaxis
six days ago at gurufocus.com         
Disposition of 10125 shares by Eastham Karin of Veracyte at 38.756 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Wolfe Research sets stock target on Veracyte, cites growth potential
Investing News at Macroaxis
over a week ago at investing.com         
Veracyte CFO Rebecca Chambers sells 585,663 in company stock
Investing News at Macroaxis
over a week ago at simplywall.st         
Veracyte, Inc. Is About To Turn The Corner
Simply Wall St News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Veracyte, Inc. Given Average Rating of Moderate Buy by Analysts
news
over two weeks ago at thelincolnianonline.com         
Veracyte Posts Quarterly Earnings Results, Beats Expectations By 0.17 EPS
news
over two weeks ago at gurufocus.com         
Wellington Management Group LLPs Strategic Reduction in Veracyte Inc Holdings
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Veracyte Inc Q3 2024 Earnings Call Highlights Record Revenue Growth and Strategic Outlook
Gurufocus Stories at Macroaxis
over two weeks ago at investing.com         
Earnings call Veracyte posts record Q3 revenue, raises 2024 guidance
Investing News at Macroaxis
a day ago at benzinga.com         
Check Out What Whales Are Doing With ALNY
benzinga news
few days ago at finance.yahoo.com         
High Growth Tech Stocks To Watch In None
Yahoo News
six days ago at thelincolnianonline.com         
Alnylam Pharmaceuticals Receives Buy Rating from HC Wainwright
news
six days ago at benzinga.com         
Regeneron Pharmaceuticalss Options A Look at What the Big Money is Thinking
benzinga news
over a week ago at seekingalpha.com         
Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis
seekingalpha News
over a week ago at businesswire.com         
Alnylam Announces Interim Phase 1 Data of Nucresiran Showing Rapid Knockdown of TTR that is Sustaine...
businesswire News
over a week ago at simplywall.st         
High Growth Tech Stocks To Watch In The Current Market
Simply Wall St News at Macroaxis
over a week ago at finance.yahoo.com         
High Growth Tech Stocks To Watch For Potential Investment
Yahoo News
over a week ago at gurufocus.com         
FMR LLC Expands Stake in Alnylam Pharmaceuticals
Gurufocus Stories at Macroaxis
over a week ago at simplywall.st         
Top Three High Growth Tech Stocks To Watch For Potential Expansion
Simply Wall St News at Macroaxis
a day ago at prnewswire.com         
WYNNEFIELD GROUP SENDS DEFINITIVE PROXY MATERIALS TO TECHPRECISION STOCKHOLDERS, INCLUDING A BLUE PR...
prnewswire News
six days ago at finance.yahoo.com         
Isle Blue Redefines Luxury Travel with Exclusive Miami Villa Collection
Yahoo News
over a week ago at gurufocus.com         
bluebird bio Inc Q3 2024 Earnings Call Highlights Navigating Revenue Challenges and ...
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Bluebird bio stock downgraded, price target slashed on financial update
Investing News at Macroaxis
over a week ago at bizjournals.com         
Bluebird bio says it needs cash to operate beyond March 2025
bizjournals News
over a week ago at gurufocus.com         
Goldman Sachs Group Incs Strategic Acquisition of Shares in bluebird bio Inc
Gurufocus Stories at Macroaxis
over two weeks ago at newswire.com         
Fusion Energy Agreement Between RSE and BLUE LASER FUSION
news
over two weeks ago at finance.yahoo.com         
Acquisition by Leschly Nick of 49850 shares of Bluebird Bio at 0.44 subject to Rule 16b-3
Yahoo News
over two weeks ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition of Shares in bluebird bio Inc
Gurufocus Stories at Macroaxis
over two weeks ago at businesswire.com         
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cel...
businesswire News
over a week ago at news.google.com         
StockNews.com Upgrades Voyager Therapeutics to Buy - MarketBeat
Google News at Macroaxis
over a week ago at investing.com         
Oppenheimer reiterates Voyager stock target, sees positive outlook from TOGETHER study
Investing News at Macroaxis
over two weeks ago at finance.yahoo.com         
Arcus Biosciences, Inc. Reports Q3 Loss, Tops Revenue Estimates
Yahoo News
over three weeks ago at news.google.com         
Voyager Therapeutics Expected to Beat Earnings Estimates Can the Stock Move Higher - Yahoo Finance
Google News at Macroaxis
over a month ago at simplywall.st         
Improved Revenues Required Before Voyager Therapeutics, Inc. Stocks 27 percent Jump Looks Justified
Simply Wall St News at Macroaxis
over a month ago at zacks.com         
GSKs NDA for UTI Drug Gepotidacin Gets FDAs Priority Review
zacks News
over a month ago at finance.yahoo.com         
Investing in Voyager Therapeutics three years ago would have delivered you a 58 percent gain
Yahoo News
over a month ago at simplywall.st         
Strong week for Voyager Therapeutics shareholders doesnt alleviate pain of five-year loss
Simply Wall St News at Macroaxis
over two months ago at news.google.com         
Voyager Therapeutics stock hits 52-week low at 5.95 - Investing.com
Google News at Macroaxis
over two months ago at finance.yahoo.com         
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabl...
Yahoo News
few days ago at investing.com         
Galapagos stock downgraded to Reduce on strategic concerns
Investing News at Macroaxis
over a week ago at gurufocus.com         
Stonepine Capital Management Reduces Stake in Evolus Inc
Gurufocus Stories at Macroaxis
over three weeks ago at thelincolnianonline.com         
Galapagos Sees Large Volume Increase Should You Buy?
news
over three weeks ago at gurufocus.com         
Galapagos NV Q3 2024 Earnings Call Highlights Strong Cash Position and RD Progress ...
Gurufocus Stories at Macroaxis
over three weeks ago at seekingalpha.com         
Galapagos Q3 2024 Earnings Preview
seekingalpha News
over three months ago at benzinga.com         
Why Trip.com Group Shares Are Trading Higher By Around 10 Here Are 20 Stocks Moving Premarket
benzinga news
over three months ago at finance.yahoo.com         
Galapagos Up on FDA Nod to Begin Phase III Lymphoma Study
Yahoo News
over three months ago at finance.yahoo.com         
ADAP 2Q24 Earnings Review Tecelra FDA Approval Capital Reload
Yahoo News
over three months ago at seekingalpha.com         
Galapagos pauses enrollment in Phase 12 study for GLPG5301
seekingalpha News
over three months ago at investorplace.com         
GLPG Stock Earnings Galapagos Beats EPS, Beats Revenue for Q2 2024
sbwire news
over a year ago at thelincolnianonline.com         
Ionis Pharmaceuticals Given New 34.00 Price Target at SVB Leerink
news
a minute ago at thelincolnianonline.com         
AbbVie Inc. Shares Sold by Janney Montgomery Scott LLC
news
2 days ago at thelincolnianonline.com         
Borer Denton Associates Inc. Has 11.52 Million Position in AbbVie Inc.
news
3 days ago at insidermonkey.com         
Are Hedge Funds Betting Big On AbbVie Inc.?
insidermonkey News
few days ago at investors.com         
AbbVie Jumps Nearly 4 percent On An Upgrade Despite Bristol Myers-Tied Setback
Investors Business Daily at Macroaxis
few days ago at forbes.com         
Which Is A Better Pick JNJ Stock Or AbbVie?
Usa forbes News
few days ago at thelincolnianonline.com         
Massachusetts Financial Services Co. MA Purchases 373,802 Shares of AbbVie Inc.
news
few days ago at thelincolnianonline.com         
Jennison Associates LLC Purchases 145,542 Shares of AbbVie Inc.
news
few days ago at thelincolnianonline.com         
Northwest Bancshares Inc. Sells 81 Shares of AbbVie Inc.
news
six days ago at thelincolnianonline.com         
AbbVie Inc. Shares Acquired by Quest Partners LLC
news
six days ago at thelincolnianonline.com         
AbbVie Inc. Shares Purchased by Meeder Asset Management Inc.
news
over a year ago at hawaiinewsnow.com         
Purchase by Sumitomo Chemical Co Ltd of 51599200 shares of Myovant Sciences
news
a minute ago at finance.yahoo.com         
Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Disease...
Yahoo News
3 days ago at www.macroaxis.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Macroaxis News
few days ago at www.macroaxis.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Macroaxis News
six days ago at investing.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Investing News at Macroaxis
over a week ago at www.macroaxis.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Macroaxis News
over a week ago at thelincolnianonline.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
news
over a week ago at gurufocus.com         
Capital International Investors Expands Stake in Sarepta Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at simplywall.st         
Sarepta Therapeutics Is Posting Healthy Earnings, But It Is Not All Good News
Simply Wall St News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
news
over two weeks ago at thelincolnianonline.com         
Sarepta Therapeutics Raised to Overweight at Cantor Fitzgerald
news
over a year ago at news.google.com         
In SOTU speech, Biden says hell veto IRA repeal efforts - FiercePharma
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Mirati Therapeutics Now Covered by Analysts at StockNews.com
news
over six months ago at finance.yahoo.com         
Billionaire Joe Lewis Pleads Guilty in Insider Trading Case
Yahoo News
over six months ago at smh.com.au         
Billionaire pleads guilty in insider trading case with a link to an Australian giant
news
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at aol.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
news
over six months ago at seekingalpha.com         
Mirati Therapeutics stock ticks higher amid Nasdaq delisting for sale to Bristol-Myers
seekingalpha News
over six months ago at thelincolnianonline.com         
Brokerages Set Mirati Therapeutics, Inc. PT at 60.00
news
over a year ago at news.google.com         
Eylea Race Continues To Heat Up With Formycon Unveiling Early ... - Generics Bulletin
Google News at Macroaxis
few days ago at news.google.com         
908 Devices earnings missed by 0.56, revenue fell short of estimates - Investing.com Nigeria
Google News at Macroaxis
over a week ago at finance.yahoo.com         
Analysts Have Lowered Expectations For 908 Devices Inc. After Its Latest Results
Yahoo News
over a week ago at bizjournals.com         
Boston firm to shift manufacturing to North Carolina
bizjournals News
over a week ago at insidermonkey.com         
908 Devices Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over a week ago at businesswire.com         
908 Devices Reports Third Quarter 2024 Financial Results and Updates 2024 Revenue Outlook
businesswire News
over two weeks ago at gurufocus.com         
What To Expect From 908 Devices Inc Q3 2024 Earnings
Gurufocus Stories at Macroaxis
over two weeks ago at simplywall.st         
US Penny Stocks 908 Devices Leads This Trio
Simply Wall St News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Hunt Anthony of 15996 shares of 908 Devices at 5.94 subject to Rule 16b-3
Macroaxis News
over a month ago at gurufocus.com         
908 Devices Inc Q2 2024 Earnings Call Highlights Strong Revenue Growth Amidst Challenges
Gurufocus Stories at Macroaxis
over two months ago at news.google.com         
908 Devices stock hits 52-week low at 3.44 amid market challenges - Investing.com
Google News at Macroaxis
a minute ago at finance.yahoo.com         
Neurocrines Phase II schizophrenia trial fails to meet primary endpoint
Yahoo News
few days ago at finance.yahoo.com         
Helpr Employer-Subsidized Family Care App with Patented My Choice Technology Expands Service to 150 ...
Yahoo News
six days ago at news.google.com         
Victory Capital Management Inc. Increases Holdings in Neurocrine Biosciences, Inc. - MarketBeat
Google News at Macroaxis
over a week ago at gurufocus.com         
BB Biotech AG Adjusts Stake in Ionis Pharmaceuticals
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
Yahoo News
over two weeks ago at finance.yahoo.com         
Neurocrine Biosciences Strong Earnings Are Of Good Quality
Yahoo News
over two weeks ago at thelincolnianonline.com         
Neurocrine Biosciences Receives Buy Rating from HC Wainwright
news
over two weeks ago at finance.yahoo.com         
Disposition of 2000 shares by Sherwin Stephen A of Neurocrine Biosciences subject to Rule 16b-3
Yahoo News
over three weeks ago at gurufocus.com         
Decoding Neurocrine Biosciences Inc A Strategic SWOT Insight
Gurufocus Stories at Macroaxis
over three weeks ago at investing.com         
Earnings call Neurocrine Biosciences reports strong Q3 growth, plans ahead
Investing News at Macroaxis
a day ago at gurufocus.com         
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Redmile Group, LLC Expands Stake in Nurix Therapeutics Inc
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Morgan Stanleys Strategic Reduction in Nurix Therapeutics Holdings
Gurufocus Stories at Macroaxis
over two weeks ago at investing.com         
Disposition of 3290 shares by Christine Ring of Nurix Therapeutics at 25.0 subject to Rule 16b-3
Investing News at Macroaxis
over three weeks ago at investing.com         
Nurix therapeutics CFO Hans van Houte sells 86,083 in stock
Investing News at Macroaxis
over three weeks ago at investing.com         
Nurix therapeutics chief scientific officer sells shares worth 83,536
Investing News at Macroaxis
over three weeks ago at thelincolnianonline.com         
Insider Selling Nurix Therapeutics, Inc. Insider Sells 3,437 Shares of Stock
news
over a month ago at globenewswire.com         
Nurix Therapeutics Announces Presentations atthe 7th Annual TPD Induced Proximity Summit
Macroaxis News: globenewswire.com
over a month ago at finance.yahoo.com         
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-...
Yahoo News
over a month ago at investing.com         
Nurix Therapeutics chief legal officer sells 82,250 in stock
Investing News at Macroaxis
over a year ago at news.google.com         
Global markets live Adobe, Eli Lilly, Nasdaq, Intel, UBS... - Marketscreener.com
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
Boxer Capital LLC Boosts Stock Position in Prometheus Biosciences, Inc.
news
over a year ago at www.macroaxis.com         
Exercise or conversion by Mark McKenna of 122528 shares of Prometheus Biosciences subject to Rule 16...
Macroaxis News
over a year ago at news.google.com         
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, L...
Google News at Macroaxis
over a year ago at simplywall.st         
We Think Prometheus Biosciences Can Afford To Drive Business Growth
Simply Wall St News at Macroaxis
over a year ago at zacks.com         
Prometheus Biosciences, Inc. is a Great Momentum Stock Should You Buy?
zacks News
over a year ago at zacks.com         
Prometheus Biosciences, Inc. Reports Q1 Loss, Tops Revenue Estimates
zacks News
over a year ago at news.google.com         
Ieq Capital LLC Sells off 35.3 percent of Holding in Prometheus ... - Best Stocks
Google News at Macroaxis
over a year ago at news.google.com         
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors - Marketscre...
Google News at Macroaxis
over a year ago at fool.com         
Why Madrigal Pharmaceuticals Stock Gained 20 percent This Week
fool News
over six months ago at www.macroaxis.com         
Disposition of 8500 shares by Jonas Jeffrey M of Karuna Therapeutics at 128.01 subject to Rule 16b-3
Macroaxis News
over six months ago at bizjournals.com         
PureTechs newest biotech spinout represents a shift from the past
bizjournals News
over six months ago at news.google.com         
Disposition of 17350 shares by Stephen Brannan of Karuna Therapeutics at 187.26 subject to Rule 16b-...
Google News at Macroaxis
over six months ago at simplywall.st         
When Will Karuna Therapeutics, Inc. Turn A Profit?
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Karuna Therapeutics, Inc. Receives Consensus Recommendation of Hold from Analysts - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics Short Position
Yahoo News
over six months ago at www.macroaxis.com         
Acquisition by Steven Paul of 47378 shares of Karuna Therapeutics at 315.18 subject to Rule 16b-3
Macroaxis News
over six months ago at seekingalpha.com         
Karuna Therapeutics stock drops on no apparent news amid deal with Bristol-Myers Squibb
seekingalpha News
over six months ago at thelincolnianonline.com         
Algert Global LLC Has 3.12 Million Stock Holdings in Karuna Therapeutics, Inc.
news
over six months ago at zacks.com         
Acquisition by Steven Paul of 27510 shares of Karuna Therapeutics at 7.27 subject to Rule 16b-3
zacks News
few days ago at news.google.com         
Brokers Set Expectations for Sutro Biopharma FY2024 Earnings - MarketBeat
Google News at Macroaxis
over a week ago at gurufocus.com         
Sutro Biopharma Inc Q3 2024 Earnings Revenue Misses Estimates at 8. ...
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition in Sutro Biopharma Inc
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
Sutro Biopharma shareholders have endured a 80 percent loss from investing in the stock three years ...
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Gerber Hans-peter of 175000 shares of Sutro Biopharma at 3.77 subject to Rule 16b-3
Macroaxis News
over a month ago at www.macroaxis.com         
Disposition of 31125 shares by Newell William J of Sutro Biopharma subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Disposition of 13380 shares by Gerber Hans-peter of Sutro Biopharma at 3.95 subject to Rule 16b-3
Macroaxis News
over two months ago at finance.yahoo.com         
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pip...
Yahoo News
over three months ago at globenewswire.com         
Sutro Biopharma Announces Initiation of REFRME-L1 Phase 2 Trial with Luvelta for Patients with Non-S...
Macroaxis News: globenewswire.com
over three months ago at simplywall.st         
Analysts Are Upgrading Sutro Biopharma, Inc. After Its Latest Results
Simply Wall St News at Macroaxis
over a year ago at news.google.com         
FDA approves Regenerons Eylea for retinopathy of prematurity - FiercePharma
Google News at Macroaxis
a day ago at thelincolnianonline.com         
Xencor, Inc. CEO Sells 1,186,121.46 in Stock
news
few days ago at investors.com         
Stocks Showing Rising Market Leadership Xencor Earns 83 RS Rating
Investors Business Daily at Macroaxis
over a week ago at finance.yahoo.com         
Wall Street Analysts Believe Xencor Could Rally 53.53 percent Heres is How to Trade
Yahoo News
over a week ago at thelincolnianonline.com         
Xencor, Inc. VP John R. Desjarlais Sells 68,684 Shares of Stock
news
over a week ago at investing.com         
Xencors SWOT analysis biotech stock faces pivotal year ahead
Investing News at Macroaxis
over a week ago at investing.com         
Disposition of 3366 shares by Bassil Dahiyat of Xencor at 15.69 subject to Rule 16b-3
Investing News at Macroaxis
over two weeks ago at simplywall.st         
Xencor, Inc. Just Reported And Analysts Have Been Cutting Their Estimates
Simply Wall St News at Macroaxis
over two weeks ago at seekingalpha.com         
Xencor GAAP EPS of -0.71 beats by 0.30, revenue of 10.71M misses by 2.62M
seekingalpha News
over two weeks ago at thelincolnianonline.com         
Xencor Announces Earnings Results, Beats Estimates By 0.27 EPS
news
over two weeks ago at finance.yahoo.com         
Xencor Reports Q3 Loss, Tops Revenue Estimates
Yahoo News
over a year ago at businesswire.com         
Verily Appoints Utpal Koppikar as Chief Financial Officer
businesswire News
over a year ago at news.google.com         
The Clock Is Ticking For Seres Therapeutics Im Not Afraid ... - Seeking Alpha
Google News at Macroaxis
few days ago at news.google.com         
Allakos Reports Q3 2024 Results and Research Progress - TipRanks
Google News at Macroaxis
over a week ago at news.google.com         
FMR LLCs Strategic Acquisition of Allakos Inc Shares - GuruFocus.com
Google News at Macroaxis
over a month ago at simplywall.st         
Allakos Insiders Miss 24 percent Gain After Offloading Stock
Simply Wall St News at Macroaxis
over a month ago at thelincolnianonline.com         
JMP Securities Reaffirms Market Outperform Rating for Allakos
news
over two months ago at news.google.com         
Allakos stock plunges to 52-week low of 0.56 amid market challenges - Investing.com
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Disposition of 13665 shares by Radford Harlan Baird of Allakos at 0.65 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Vanguard Group Inc. Raises Stock Holdings in Allakos Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Allakos stock plunges to 52-week low of 0.67 amid steep annual decline - Investing.com
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
Yahoo News
over three months ago at finance.yahoo.com         
Can Allakos Afford To Invest In Growth?
Yahoo News
a day ago at investing.com         
Jefferies reaffirms Buy rating on argenx stock, ups target amid promising trial updates
Investing News at Macroaxis
few days ago at gurufocus.com         
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Gurufocus Stories at Macroaxis
over a week ago at insidermonkey.com         
Is argenx SE the Best Immunotherapy Stock to Buy Now?
insidermonkey News
over a week ago at gurufocus.com         
Deep Track Capital, LP Increases Stake in Vigil Neuroscience Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Artisan Partners Limited Partnership Adjusts Stake in RxSight Inc
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
argenx stock boosted by Wolfe, citing dominance in MG and profitability ahead
Investing News at Macroaxis
over two weeks ago at finance.yahoo.com         
Is Argenx Outperforming Other Medical Stocks This Year?
Yahoo News
over two weeks ago at zacks.com         
Why Argenx Might be Well Poised for a Surge
zacks News
over three weeks ago at seekingalpha.com         
Argenx SE reports Q3 results
seekingalpha News
over three weeks ago at thelincolnianonline.com         
Truist Financial Forecasts Strong Price Appreciation for argenx Stock
news
few days ago at news.google.com         
Ascendis Pharmas SWOT analysis stock faces growth hurdles amid pipeline promise - Investing.com Indi...
Google News at Macroaxis
over a week ago at simplywall.st         
Ascendis Pharma Third Quarter 2024 Earnings Misses Expectations
Simply Wall St News at Macroaxis
over a week ago at investing.com         
Oppenheimer cuts Ascendis Pharma stock target, outperform on Q3 report
Investing News at Macroaxis
over a week ago at investing.com         
TD Cowen cuts Ascendis Pharma target to 153, keeps buy rating
Investing News at Macroaxis
over a week ago at gurufocus.com         
T. Rowe Price Investment Management, Inc. Expands Holdings in Ascendis Pharma AS
Gurufocus Stories at Macroaxis
over a week ago at seekingalpha.com         
Ascendis Pharma GAAP EPS of -1.72, revenue of 57.83M
seekingalpha News
over a week ago at seekingalpha.com         
Ascendis Pharma Q3 2024 Earnings Preview
seekingalpha News
over two weeks ago at finance.yahoo.com         
Heres Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical
Yahoo News
over two weeks ago at benzinga.com         
Novo Nordisk Q3 Preview Will 285 Million Weight Loss Bet Offset Bearish Charts?
benzinga news
over two weeks ago at medcitynews.com         
Novo Nordisk Commits 285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs
news
over a year ago at news.google.com         
Taysha The FDA Just Stuck A Major Blow To Their Plans - Seeking Alpha
Google News at Macroaxis
a day ago at thelincolnianonline.com         
Royal Bank of Canada Lowers Biohaven Price Target to 58.00
news
over a week ago at gurufocus.com         
Janus Henderson Group PLCs Strategic Acquisition of Biohaven Ltd Shares
Gurufocus Stories at Macroaxis
over a week ago at thelincolnianonline.com         
Royal Bank of Canada Lowers Biohaven Price Target to 66.00
news
over a week ago at investing.com         
Biohaven shares rise as TD Cowen lifts price target to 75
Investing News at Macroaxis
over a month ago at dragonflycap.com         
How this Weeks Premium Top 10 Performed, October 25, 2024
news
over a month ago at dragonflycap.com         
Top Trade Ideas for the Week of October 21, 2024 The Best
news
over a month ago at thelincolnianonline.com         
Biohaven Receives Overweight Rating from Cantor Fitzgerald
news
over a month ago at simplywall.st         
Vladimir Coric Buys Handful Of Shares In Biohaven
Simply Wall St News at Macroaxis
over a month ago at finance.yahoo.com         
Bullish Biohaven Insiders Loaded Up On US41.7m Of Stock
Yahoo News
over a month ago at prnewswire.com         
Biohaven Announces Pricing of 250 Million Public Offering of Common Shares
prnewswire News
a day ago at finance.yahoo.com         
AffyImmune Appoints Deyaa Adib, MD as Chief Medical Officer
Yahoo News
few days ago at news.google.com         
Disposition of 9824 shares by Coats Lonnel of Blueprint Medicines at 94.87 subject to Rule 16b-3
Google News at Macroaxis
over a week ago at news.google.com         
Prime Capital Investment Advisors LLC Sells 6,476 Shares of Blueprint Medicines Co. - MarketBeat
Google News at Macroaxis
over a week ago at investing.com         
Blueprint Medicines stock underpriced with 2bn peak sales in sight, per JPMorgan
Investing News at Macroaxis
over two weeks ago at thelincolnianonline.com         
97,861 Shares in Blueprint Medicines Co. Bought by MG Plc
news
over three weeks ago at thelincolnianonline.com         
Blueprint Medicines Co. Shares Bought by Emerald Advisers LLC
news
over three weeks ago at thelincolnianonline.com         
Blueprint Medicines Buy Rating Reaffirmed at Needham Company LLC
news
over three weeks ago at thelincolnianonline.com         
Wedbush Boosts Earnings Estimates for Blueprint Medicines
news
over three weeks ago at thelincolnianonline.com         
Wedbush Research Analysts Lift Earnings Estimates for BPMC
news
over three weeks ago at zacks.com         
Blueprint Medicines Reports Q3 Loss, Tops Revenue Estimates
zacks News
few days ago at globenewswire.com         
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific An...
Macroaxis News: globenewswire.com
few days ago at kalkinemedia.com         
Celldex Therapeutics Insider Makes US308k Share Purchase
news
over a week ago at gurufocus.com         
Polar Capital Holdings Plc Reduces Stake in Celldex Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Allakoss SWOT analysis biotech firms stock faces hurdles in CSU market
Investing News at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Marucci Anthony S of 11500 shares of Celldex Therapeutics at 26.82 subject to Rule 16...
Macroaxis News
over two weeks ago at simplywall.st         
Celldex Therapeutics Third Quarter 2024 Earnings Beats Expectations
Simply Wall St News at Macroaxis
over two weeks ago at investing.com         
Stifel maintains buy on THRD with 23 target on study outlook
Investing News at Macroaxis
over two weeks ago at finance.yahoo.com         
Celldex Q3 Earnings Snapshot
Yahoo News
over three weeks ago at zacks.com         
Intra-Cellular Therapies Reports Q3 Loss, Tops Revenue Estimates
zacks News
over a month ago at gurufocus.com         
Celldex Therapeutics Reports Positive Results in Chronic Inducible Urticaria Study
Gurufocus Stories at Macroaxis
a day ago at investing.com         
Piper Sandler stays bullish on Cogent shares, cites clinical profile strength for bezu
Investing News at Macroaxis
over a week ago at thelincolnianonline.com         
What is Lifesci Capitals Forecast for COGT FY2024 Earnings?
news
over a week ago at investing.com         
Cogent shares target cut, retains buy rating on Q3 earnings
Investing News at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Ros Matthew of 60000 shares of Cogent Biosciences at 8.45 subject to Rule 16b-3
Macroaxis News
over three weeks ago at www.macroaxis.com         
Acquisition by Ros Matthew of 1900 shares of Cogent Biosciences at 10.75 subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC...
Yahoo News
over a month ago at www.macroaxis.com         
Acquisition by Ferrante Karen Jean of 2034 shares of Cogent Biosciences at 10.75 subject to Rule 16b...
Macroaxis News
over two months ago at news.google.com         
Cogent Biosciences price target raised to 15 from 13 at Citi - TipRanks
Google News at Macroaxis
over two months ago at simplywall.st         
Cogent Biosciences Is In A Good Position To Deliver On Growth Plans
Simply Wall St News at Macroaxis
over three months ago at news.google.com         
COGT Operating Margin percent 0.00 percent - GuruFocus.com
Google News at Macroaxis
a day ago at finance.yahoo.com         
Exact Sciences Advances Breast Cancer Care with the Oncotype DX test and Genomic Profiling Research ...
Yahoo News
six days ago at gurufocus.com         
Exact Sciences Corp Shares Up 8.93 percent on Nov 19
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Exact Sciences Corp Shares Gap Down to 49.33 on Nov 16
Gurufocus Stories at Macroaxis
over a week ago at businesswire.com         
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conferen...
businesswire News
over two weeks ago at thelincolnianonline.com         
Piper Sandler Cuts Exact Sciences Price Target to 75.00
news
over two weeks ago at thelincolnianonline.com         
TD Cowen Cuts Exact Sciences Price Target to 82.00
news
over two weeks ago at thelincolnianonline.com         
Jefferies Financial Group Raises Exact Sciences Price Target to 85.00
news
over two weeks ago at insidermonkey.com         
Exact Sciences Corporation Q3 2024 Earnings Call Transcript
insidermonkey News
over two weeks ago at benzinga.com         
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst S...
benzinga news
over two weeks ago at finance.yahoo.com         
Exact Sciences Corp Q3 2024 Earnings Call Highlights Strong Revenue Growth Amid ...
Yahoo News
a day ago at investing.com         
Kura Oncologys SWOT analysis precision cancer drug stock faces pivotal year
Investing News at Macroaxis
3 days ago at finance.yahoo.com         
Kura Oncology, Inc. Among the Most Promising Cancer Stocks According to Hedge Funds
Yahoo News
few days ago at investors.com         
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26
Investors Business Daily at Macroaxis
few days ago at seekingalpha.com         
Analysts supportive of KuraKirin deal despite major selloff in shares
seekingalpha News
few days ago at seekingalpha.com         
Kura stock slides 17 percent on Kyowa Kirin deal for ziftomenib
seekingalpha News
over a week ago at gurufocus.com         
Paradigm Biocapital Advisors LP Adjusts Stake in Kura Oncology Inc
Gurufocus Stories at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Wilson Troy Edward of 300000 shares of Kura Oncology subject to Rule 16b-3
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Kura Oncologys Outperform Rating Reiterated at Wedbush
news
over two weeks ago at finance.yahoo.com         
Kura Oncology Q3 Earnings Snapshot
Yahoo News
over three weeks ago at simplywall.st         
Kura Oncology Has Debt But No Earnings Should You Worry?
Simply Wall St News at Macroaxis
over a year ago at www.macroaxis.com         
Payment of 635 shares by Stephen Webster of Spark Therapeutics subject to Rule 16b-3
Macroaxis News
a day ago at investing.com         
Acquisition by Thornberry Nancy of 1571 shares of Vertex Pharmaceuticals at 9.71 subject to Rule 16b...
Investing News at Macroaxis
3 days ago at thelincolnianonline.com         
Pacer Advisors Inc. Sells 5,885 Shares of Vertex Pharmaceuticals Incorporated
news
few days ago at finance.yahoo.com         
Goldman Sachs Vertex Pharmaceuticals Incorporated Is A Top Growth Investor Stock
Yahoo News
few days ago at dailygalaxy.com         
Extinct for 16 Million Years, This Ancient Species Returns to Stun Scientists
news
few days ago at investing.com         
Vertex trust sells 3.79 million in shares
Investing News at Macroaxis
few days ago at finance.yahoo.com         
Cision to Transform AI-Powered Communications in Collaboration with Google Cloud
Yahoo News
few days ago at forbes.com         
Buy Signal Flashing For Struggling Biotech
Usa forbes News
six days ago at zacks.com         
Vertex Pharmaceuticals Incorporated is Attracting Investor Attention Here is What You Should Know
zacks News
six days ago at gurufocus.com         
Disposition of tradable shares by Altshuler David of Vertex Pharmaceuticals at 478.56 subject to Rul...
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Vertex CEO David DeStefano sells 9.8 million in shares
Investing News at Macroaxis
3 days ago at thelincolnianonline.com         
Benjamin L. Palleiko Sells 14,400 Shares of KalVista Pharmaceuticals, Inc. Stock
news
over a week ago at www.macroaxis.com         
Disposition of 8077 shares by Audhya Paul K. of Kalvista Pharmaceuticals at 9.2566 subject to Rule 1...
Macroaxis News
over a week ago at gurufocus.com         
Vestal Point Capital, LP Increases Stake in KalVista Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over two weeks ago at businesswire.com         
KalVista Pharmaceuticals Announces Pricing of a 55 Million Underwritten Offering of Common Stock and...
businesswire News
over two weeks ago at seekingalpha.com         
KalVista prices 55M stock offering
seekingalpha News
over a month ago at finance.yahoo.com         
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American Colle...
Yahoo News
over a month ago at businesswire.com         
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American Colle...
businesswire News
over a month ago at finance.yahoo.com         
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over a month ago at gurufocus.com         
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc
Gurufocus Stories at Macroaxis
a day ago at finance.yahoo.com         
Are Medical Stocks Lagging AnaptysBio This Year?
Yahoo News
six days ago at investing.com         
Truist maintains hold on AnaptysBio with 30 target
Investing News at Macroaxis
over a week ago at thelincolnianonline.com         
AnaptysBio Price Target Lowered to 66.00 at JPMorgan Chase Co.
news
over two weeks ago at zacks.com         
Down -32.84 percent in 4 Weeks, Heres Why You Should You Buy the Dip in AnaptysBio
zacks News
over two weeks ago at finance.yahoo.com         
AnaptysBio Third Quarter 2024 Earnings Beats Expectations
Yahoo News
over two weeks ago at gurufocus.com         
AnaptysBio Inc Q3 2024 Earnings Revenue Soars to 30M, EPS Beats Estimates at -1.14
Gurufocus Stories at Macroaxis
over two weeks ago at investing.com         
AnaptysBio shares hold Outperform rating Leerink notes strong cash position and clinical progress
Investing News at Macroaxis
over two weeks ago at finance.yahoo.com         
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Yahoo News
over two weeks ago at zacks.com         
AnaptysBio, Inc. Reports Q3 Loss, Tops Revenue Estimates
zacks News
over three weeks ago at gurufocus.com         
AnaptysBio Shares Plunge as Eli Lilly Ends Arthritis Drug Research
Gurufocus Stories at Macroaxis
few days ago at globenewswire.com         
uniQure Announces Dosing of First Patient in GenTLE Phase IIIa Clinical Trial of AMT-260 for the Tre...
Macroaxis News: globenewswire.com
few days ago at thelincolnianonline.com         
uniQure Announces Dosing of First Patient in GenTLE Phase IIIa Clinical Trial of AMT-260 for Refract...
news
over two weeks ago at thelincolnianonline.com         
Royal Bank of Canada Has Lowered Expectations for uniQure Stock Price
news
over two weeks ago at finance.yahoo.com         
What Does The Future Hold For uniQure N.V. These Analysts Have Been Cutting Their Estimates
Yahoo News
over two weeks ago at finance.yahoo.com         
UniQure Q3 Earnings Snapshot
Yahoo News
over three weeks ago at zacks.com         
Select Medical Q3 Earnings and Revenues Surpass Estimates
zacks News
over a month ago at thelincolnianonline.com         
uniQure Raised to Sell at StockNews.com
news
over a month ago at finance.yahoo.com         
uniQure Announces Dosing of First Patient in Phase III Clinical Trial of AMT-162 for the Treatment S...
Yahoo News
over a month ago at zacks.com         
Strength Seen in Dianthus Therapeutics, Inc. Can Its 5.7 percent Jump Turn into More Strength?
zacks News
over two months ago at www.macroaxis.com         
Acquisition by Gut Robert of 17060 shares of Uniqure NV at 20.18 subject to Rule 16b-3
Macroaxis News
few days ago at thelincolnianonline.com         
Sage Therapeutics Upgraded at Royal Bank of Canada
news
few days ago at finance.yahoo.com         
Sage ends dalzanemdor development following Phase II trial failure
Yahoo News
few days ago at benzinga.com         
After Failed Alzheimers Study, Sage Therapeutics Dalzanemdor Flunks Another Study In Patients With I...
benzinga news
six days ago at kalkinemedia.com         
Online Payroll Service Market Is Booming Worldwide Major Giants ADP, Gusto, Sage, Paychex
news
over two weeks ago at finance.yahoo.com         
With Trump victorious, biotech industrys focus turns to his plans for FDA, FTC
Yahoo News
over two weeks ago at thelincolnianonline.com         
Sage Therapeutics, Inc. Receives 13.76 Average PT from Brokerages
news
over three weeks ago at thelincolnianonline.com         
Sage Therapeutics Announces Quarterly Earnings Results
news
over three weeks ago at insidermonkey.com         
Sage Therapeutics, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over three weeks ago at gurufocus.com         
Sage Therapeutics Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth Amid ...
Gurufocus Stories at Macroaxis
over three weeks ago at seekingalpha.com         
Sage stock plunges 18 percent post-market following business update, earnings
seekingalpha News
Far too much social signal, news, headlines, and media speculation about Eventide Healthcare that are available to investors today. That information is available publicly through Eventide media outlets and privately through word of mouth or via Eventide internal channels. However, regardless of the origin, that massive amount of Eventide data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eventide Healthcare news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eventide Healthcare relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eventide Healthcare's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eventide Healthcare alpha.

Other Information on Investing in Eventide Mutual Fund

Eventide Healthcare financial ratios help investors to determine whether Eventide Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eventide with respect to the benefits of owning Eventide Healthcare security.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities